US 11,913,066 B2
SE33 mutations impacting genotype concordance
Robert Green, Carlsbad, CA (US); Dennis Wang, Dublin, CA (US); Julio Mulero, Carlsbad, CA (US); and Robert Lagace, Oakland, CA (US)
Assigned to Life Technologies Corporation, Carlsbad, CA (US)
Filed by Life Technologies Corporation, Carlsbad, CA (US)
Filed on Jan. 26, 2022, as Appl. No. 17/585,161.
Application 17/585,161 is a division of application No. 15/614,582, filed on Jun. 5, 2017, granted, now 11,248,256.
Application 15/614,582 is a division of application No. 14/809,418, filed on Jul. 27, 2015, abandoned.
Application 14/809,418 is a division of application No. 13/239,335, filed on Sep. 21, 2011, granted, now 9,090,946, issued on Jul. 28, 2015.
Claims priority of provisional application 61/466,920, filed on Mar. 23, 2011.
Claims priority of provisional application 61/385,094, filed on Sep. 21, 2010.
Prior Publication US 2022/0205023 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6827 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6888 (2018.01)
CPC C12Q 1/6827 (2013.01) [C12Q 1/6888 (2013.01); C12Q 1/686 (2013.01); C12Q 2537/143 (2013.01); C12Q 2600/156 (2013.01)] 8 Claims
 
1. A method for amplifying a nucleic acid comprising:
a. providing at least one forward primer capable of annealing to SE33 locus 5′ of a STR region,
b. providing at least a first reverse primer capable of annealing to the SE33 locus 3′ of the STR region, wherein said reverse primer comprises at least 20 contiguous nucleotides comprising positions 316, 317, and 324 of the inverse complement of SEQ ID NO: 3, wherein SEQ ID NO: 3 comprises an adenosine at position 317 or an adenosine at position 324, and wherein the at least one forward primer comprises a fluorescent label; and
c. amplifying the nucleic acid using the forward and reverse primers.